Kengo Matsunaga

Saitama International Medical Center

Papers

1

Total Citations

6

H-Index

1

About

Kengo Matsunaga is a cancer genomics researcher whose work centers on the molecular mechanisms driving renal cell carcinoma, particularly the role of the *VHL* tumor suppressor gene. His most-cited study, “Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential *VHL* Mutations Underlie Multifocal ccRCC” (2022, 6 citations), provides critical insight into how chromosomal rearrangements and subsequent *VHL* alterations drive the development of multiple, independent clear cell renal cell carcinoma (ccRCC) tumors in the same patient. By tracing the evolution of derivative chromosome 3 loss and its link to *VHL* inactivation—which disrupts the degradation of HIFα and promotes tumorigenesis—Matsunaga’s work clarifies a key pathway in ccRCC initiation. This research has important implications for understanding tumor heterogeneity and for guiding personalized surveillance or treatment strategies in patients with multifocal disease. Though early in his career, Matsunaga’s focused contributions to the genetics of kidney cancer are already helping to map the complex genomic landscape of this disease, offering a foundation for future translational studies.

Research Focus

Key Achievements

1
H-Index
1
Papers
6
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential<i>VHL</i>Mutations Underlie Multifocal ccRCC
6 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 13
🏛 Institutions: Saitama International Medical Center

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago